Current Trials

CM5521 Atopic Dermatitis Treatment

 CMAX Clinical Research

Atopic Dermatitis (otherwise known as atopic eczema) affects both children & adults, and can cause lifelong issues for patients.

The Fusion team is working with CMAX to conduct a Phase I Trial testing a topical gel in patients with mild to moderate Atopic Dermatitis (AD). This study will take place at CMAX in the CBD.

Call 1800 150 433 today to learn more and discuss your eligibility!

nati-I-6Ap7JXHq8-unsplash

Eligibility requirements

  • Age: 18+
  • Sex: Males & Females
  • BMI: ≥40 kg
  • Weight: ≥40 kg
  • Medication: Have not received other recent treatment for AD No vaccines within 30 days
  • Medical History: Mild to moderate Atopic Dermatitis ≥ 3 months No other dermatological conditions

Overnight Stays

  • No Overnight Stays

Outpatient Visits

  • 8 Visits over 3 weeks, Telehealth Appointments for Home Dosing

Payment/Renumeration

  • $2,420

How to apply

To register your interest in this trial, please complete this form. A Fusion team member will be in contact to discuss your eligibility shortly.